




TECH CENTER 1600/2900

JUL 11 2002

RECEIVED

CLAIMS AS CURRENTLY PENDING IN THE APPLICATION

1. A compound of the following structural formula:



and pharmaceutically acceptable salts thereof wherein;

$R_1$  and  $R_2$  are independently hydrogen,  $C_{1-6}$  alkyl, or  $R_1$  and  $R_2$  are joined to form pyrrolidine, piperidine, morpholine or imidazole;

$X$  is  $OCH_3$ ,  $SO_2R_3$ ,  $SO_2CF_3$  or  $CN$ ;

$R_3$  is  $C_{1-6}$  alkyl or a  $C_{5-10}$  aromatic ring (optionally substituted with a halogen, hydroxyl or  $C_{1-6}$  alkyl optionally substituted with halogen or hydroxyl); and  $Y$  is hydrogen,  $Cl$ ,  $Br$ ,  $F$ ,  $CN$ ,  $CONR_1R_2$ ,  $CF_3$ ,  $OCH_3$ ,  $SO_2NR_1R_2$ .

2. The compound of claim 1 wherein  $R_1$  and  $R_2$  are each propyl.

3. The compound of claim 1 wherein  $R_1$  and  $R_2$  are each methyl.

4. The compound of claim 1 wherein  $X$  is  $-OCH_3$ .

5. The compound of claim 1 wherein  $Y$  is hydrogen.

6. The compound of claim 1 which is



TECH CENTER 1001-2011

JUL 11 2007

RECEIVED

(R)-5-Methylamino-1-methoxy-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one;

b) (R)-5-Dimethylamino-1-methoxy-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one;

c) (R)-5-Propylamino-1-methoxy-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one;

d) (R)-5-Dipropylamino-1-methoxy-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one.

7. A method for treating anxiolytic disorders in animal or human hosts comprising the administration of a pharmaceutically effective amount of a compound of Formula I as set forth in claim 1.

8. The method of claim 7 wherein said compound is orally administered in an amount of from about 10 mg to about 1200 mg per day.

9. (R)-3-Methylamino-1,2,3,4-tetrahydroquinoline maleate.

10. (R)-3-Methyl-1,2,3,4-tetrahydro-3-quinolinyl carbamic acid, phenylmethyl ester.

11. (R)-3-Methyl-1,2,3,4-tetrahydro-1-[methoxyamino]carbonyl-3-quinolinyl carbamic acid, phenylmethyl ester.


12. Methyl-(1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolinyl-5-yl)carbamic acid, phenylmethyl ester.

13. A compound of the following structural formula:

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900



and pharmaceutically acceptable salts thereof wherein;

$R_1$  and  $R_2$  are independently hydrogen,  $C_{1-6}$  alkyl, or carboxybenzyl or  $R_1$  and  $R_2$  are joined to form pyrrolidine, piperidine, morpholine or imidazole;

$R_3$  and  $R_4$  are joined to form an X-substituted-imidazolin-2-one, -CONX-, when  $C_3$  is either the R- or S-configuration;

X is  $OCH_3$ ,  $SO_2R_5$ ,  $SO_2CF_3$ , or CN;

$R_5$  is  $C_{1-6}$  alkyl or a  $C_{5-10}$  aromatic ring (optionally substituted with a halogen or hydroxyl); and

Y is hydrogen, Cl, Br, F, CN,  $CONR_1R_2$ ,  $CF_3$ ,  $OCH_3$ ,  $SO_2NR_1R_2$ ; and if

$R_1$  is hydrogen,  $R_2$  is methyl, and  $C_3$  is the R-configuration,  $R_3$  and  $R_4$  are hydrogen; and if

$R_1$  is methyl,  $R_2$  is carboxybenzyl,  $C_3$  is the R-configuration, and  $R_3$  is hydrogen or  $-CO(NH)OCH_3$ ,  $R_4$  is hydrogen.